About: Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $153.41 (+1.89%)
PVLA NASDAQ Palvella Therapeutics, Inc
Palvella Therapeutics, Inc share price
PVLA price activity
Last Price
$153.410
Change (24hr)
2.85 USD (1.89%)
Volume
123.47K
Volume (4w avg)
-
Open
$152.40
Day Range
$151.31 - $155.11
Previous Close
$150.56
Last Trade
21 Sep, 8:20 pm GMT+0
Delayed
21 Sep, 8:20 pm GMT+0
PVLA price performance
Delayed
21 Sep, 8:20 pm GMT+0
PVLA Market Signals